Pipeline

JY BioMedical has a robust and innovative R&D pipeline focused on developing advanced therapies for various medical conditions. The company’s cutting-edge research includes the development of DC-PDL1 and DC-WT1 cancer vaccines, which aim to enhance the immune system's ability to target cancer cells. These vaccines are designed to stimulate dendritic cells (DCs) to present specific tumor antigens, such as PDL1 and WT1, improving the body’s immune response against cancer.

​

In addition to cancer vaccines, JY BioMedical is pioneering work in DC-derived exosomes (DEX). Exosomes are small vesicles that play a role in cell communication and can be engineered to carry tumor antigens, enhancing the immune system’s attack on cancer cells. This approach shows promise in improving the efficacy of immunotherapies by promoting targeted immune responses while reducing systemic side effects.

​

Furthermore, the company is developing antibody-drug conjugates (ADCs) targeting CEACAM6, a cell surface protein often overexpressed in certain types of cancer. ADCs are engineered to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy tissues and improving therapeutic precision. By focusing on CEACAM6, JY BioMedical aims to create highly specific treatments for cancers that express this protein.

​

A key area of innovation for JY BioMedical is its exploration of the therapeutic potential of Gamma-Delta (γδ) T cells. These unique immune cells, particularly the Vδ1 and Vδ2 subtypes, have demonstrated broad anti-tumor activity and strong cytotoxicity, offering potential treatments for a range of malignancies. Their ability to recognize and kill cancer cells without the need for antigen presentation makes them a versatile tool in the fight against cancer.

​

JY BioMedical is also advancing research on mesenchymal stem cells (MSCs) and MSC-derived exosomes, with a strong focus on regenerative medicine. MSCs are known for their ability to promote tissue repair and modulate immune responses, making them ideal candidates for treating inflammatory and neurodegenerative diseases. The company is exploring MSC applications in wound healing, neuroprotection, and the treatment of various inflammatory conditions, leveraging MSC-derived exosomes for their ability to deliver therapeutic signals to damaged tissues.

​

Through these cutting-edge initiatives, JY BioMedical aims to revolutionize cancer treatment and regenerative medicine by offering more effective, targeted therapies with fewer side effects than traditional approaches.